

COPY

Commercial Solvents Corporation,
17, East Forty-Second Street,
New York, 17, N.Y.

July 26th, 1951.

Dr. E. Klieneberger-Nobel,
Lister Institute of Preventive Medicine,
London, England.

Dear Dr. Klieneberger,

We have been following your work on the filterable forms of bacteria with a great deal of interest, especially because of the marked similarity between your findings and those of our Group in respect to the acid-fast bacteria in particular. As you are probably aware we have been finding organisms of this type routinely in all cases of proliferative diseases including the various forms of neoplasia. As a result of these studies and those of Dr. Diller and her Associates at the Institute for Cancer Research in Philadelphia, it has been decided to hold an international conference on, The Microbiology of Cancer.

The first two sessions will be devoted to the fundamental bacteriological aspects of the problem. The background history leading to the discovery of the constant presence of certain pleomorphic acid-fast organisms in a wide variety of the chronic proliferative diseases including cancer will be reviewed. The incidence of microbial agents both fungal and bacterial in both animal and human cases of malignant disease, their primary isolation, their morphologic appearance, their growth requirements and other cultural characteristics will be described. Animal experiments demonstrating the pathogenicity of these organisms and their possible etiologic relationship to the development of neoplasia will be reported. The third and fourth sessions will be designed to cover particularly the immunologic and therapeutic aspects.

While the idea of having a Symposium covering the Microbiologic Aspects of Cancer has been discussed repeatedly and under serious consideration for the past month or so, final decision on asking the Academy of Sciences to sponsor such a program in conjunction with a companion meeting on the Viral Aspects of Cancer was only definitely decided upon a few days ago and approved in principle by the Conference Committee of that organization. I hope this will explain the reason for giving you such short notice in extending you an invitation to participate in the program. Due to the fact the latter program will follow ours, we hope that you shall be able to attend both of these. We hope that you will take advantage of your visit and spend some little time here and of course,

we expect you to visit both Laboratories in Philadelphia and our own.

We assume you will probably need some financial assistance to attend these meetings. Ways and means have not been worked out in detail yet, but we feel certain we can obtain some certain funds to aid you in some, if not all, of your travel expenditures.

Because of the urgency of submitting the complete program to the Academy Council for final approval by the end of the month, I would appreciate it if you would advise me whether you will be able to take part in the program and if you can accept our invitation, to forward me the proposed title of your paper within a short time. I would also appreciate your letting me have your name, title and institution affiliation in exactly the way you wish it to appear in the printed program. Your talk is scheduled for November 14th, for an allotted time of thirty minutes.

Sincerely yours,

(signed) Lawrence W. Smith, M.D.

LWS:re